SCHEMBL7189743

SCHEMBL7189743

COc1ccc(-c2ccc3cc(OC)ccc3c2Oc2ccc(C=O)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
CYP2A6 P11509 1/20 0.49
GSTP1 P09211 1/20 0.42
ESR1 P03372 4/20 0.40
ESR2 Q92731 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSP90AA1 P07900 1/20 0.39
KDM4E B2RXH2 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PLAU P00749 1/20 0.38
SLC2A1 P11166 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
MAPT P10636 2/20 0.38
PTGER4 P35408 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182654 0.93 ALOX5 (0.43) ALDH1A1CYP2A6GSTP1ESR1MAPT
SCHEMBL7191254 0.93 ESR1 (0.44) ALDH1A1CYP2A6GSTP1ESR1ESR2
SCHEMBL3120120 0.91 CYP1A2 (0.44) ALDH1A1CYP2A6GSTP1ESR1ESR2
SCHEMBL7189972 0.89 MAPT (0.44) ALDH1A1CYP2A6GSTP1CYP1A2PLAU
SCHEMBL6050146 0.89 GSTP1 (0.43) ALDH1A1CYP2A6GSTP1ESR1ESR2
SCHEMBL7187373 0.87 ALDH1A1 (0.49) ALDH1A1CYP2A6ESR1ESR2SMN1; SMN2
SCHEMBL7190071 0.86 GSTP1 (0.39) ALDH1A1CYP2A6GSTP1CYP1A2SLC2A1
SCHEMBL7194282 0.86 ERN1 (0.39) ALDH1A1CYP2A6GSTP1ESR1ESR2
SCHEMBL7188354 0.85 RELA (0.42) ALDH1A1CYP2A6GSTP1ESR1ESR2
SCHEMBL1359561 0.85 ESR1 (0.47) ALDH1A1CYP2A6GSTP1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0835867-B1 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods LILLY CO ELI (US) 2003-12-03 EP disclosed
US-6355632-B1 AROMATIC ETHER AMINES FOR TREATMENT OF OSTEOPOROSIS ELI LILLY AND COMPANY 2002-03-12 US disclosed
US-6268361-B1 ESTROGEN DEPENDENT DISORDERS INCLUDING CANCER, ENODMETRIOSIS, ETC PALKOWITZ ALAN D (US) 2001-07-31 US disclosed
US-5998401-A POSTMENOPAUSE THERAPY ELI LILLY AND COMPANY (US) 1999-12-07 US disclosed
US-5916916-A USEFUL AS SELECTIVE ESTROGEN RECEPTOR MODULATORS. ELI LILLY AND COMPANY (US) 1999-06-29 US disclosed
EP-0729951-B1 Naphthyl compounds, intermediates, compositions, and methods LILLY CO ELI (US) 1999-06-02 EP disclosed
EP-0835867-A1 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods ELI LILLY AND COMPANY (US) 1998-04-15 EP disclosed
US-5574190-A AROMATIC ETHER DERIVATIVES FOR TREATMENT OF HORMONE DEPENDENT CANCER SUCH AS BREAST CANCER ELI LILLY AND COMPANY (US) 1996-11-12 US disclosed
US-5567712-A THERAPY FOR ENDOMETRIOSIS ELI LILLY AND COMPANY (US) 1996-10-22 US disclosed
EP-0729951-A1 Naphthyl compounds, intermediates, compositions, and methods ELI LILLY AND COMPANY (US) 1996-09-04 EP disclosed